Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May 20;7(4):e756.
doi: 10.1212/NXI.0000000000000756. Print 2020 Jul.

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy

Christoph Mahler  1 , Michael Andrews  1 , Sian M Henson  1 , Sharmilee Gnanapavan  2
Affiliations
Case Reports

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy

Christoph Mahler et al. Neurol Neuroimmunol Neuroinflamm. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure. Antiviral immune response and PML lesion evolution after treatment with IL2 and pembrolizumab for case 1 and 2
Shown is the percentage of PD-1+ in CD4+ and CD8+ T-cells in blood and the JC virus DNA titer in CSF (A and B) and lymphocyte subpopulations in blood (case 1: A, case 2: B) (C) case 2 PD-1+ % in blood vs age-matched control (control PD-1+) and JC virus DNA titer in the CSF. Evolution of the PML lesion in MRI (D) case 1, (E) case 2, top: T2/FLAIR, middle: T2/FLAIR lesion area pseudocolored in yellow, differential increase (red), differential reduction (green), bottom: B1000 DWI. Treatment bar: brown for IL2 and yellow for PD1. *Marks drop in lymphocyte subpopulations in case 2 secondary to dose escalation of IL-2 to 2.07 million units/m2. JC = John Cunningham; PD-1 = programmed cell death protein-1; PML = Progressive multifocal leukoencephalopathy.
See this image and copyright information in PMC

References

    1. Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 2019;380:1597–1605. - PubMed
    1. Kupper C, Heinrich J, Kamm K, et al. Pembroluzimab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm 2019;6:e628 doi: 10.1212/NXI.0000000000000628. - DOI - PMC - PubMed
    1. Gascó AF, Vericat JM, Albir MC, et al. CP-070 Interleukin-2 treatment of two patients with multifocal progressive leukoencephalopathy associated with hiv infection. Eur J Hosp Pharm 2017;24:A31.
    1. Durali D, de Goër Herve MG, Gasnault J, Taoufik Y. B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol 2015;6:241. - PMC - PubMed
    1. Taoufik Y, de Goër Herve MG. Editorial: immune control of JC virus infection and immune failure during progressive multifocal leukoencephalopathy. Front Immunol 2017;8:1646. - PMC - PubMed

Publication types

MeSH terms